Antipsychotic Prescribing and Delirium Outcomes at a Mexican Tertiary Referral Center: A Retrospective Cohort
Clinical Pharmacy Connect · 18.11.2026
DOI: 10.69709/cpc.2026.120064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacy Connect, online erschienen am 18.11.2026. Verfasst von Alejandro Salazar-Rodríguez und 6 weiteren Autor:innen.
Themen: Delir
Abstract (Originalsprache)
Background
Haloperidol remains the default antipsychotic for hospital delirium in much of the world, yet prescribing practice and measured outcomes have rarely been described together in Latin American hospitals.
Methods
Retrospective cohort of consecutive adults with delirium seen by consultation-liaison psychiatry at a Mexico City tertiary referral centre (March 2021 to August 2022). Severity was the summed CAM-S short-form score (0–7) at each psychiatric visit; each patient contributed one index antipsychotic regimen. We modelled CAM-S with linear mixed models and estimated cumulative incidence of first resolution (CAM-S = 0) with the Aalen–Johansen estimator, treating in-hospital death as a competing event. No comparative-effectiveness hypothesis was prespecified.
Results
Of 195 screened records, 136 patients contributing 724 assessments were analysed; haloperidol accounted for 115 regimens (84.6%). CAM-S fell by 0.38 points per day (95% CI 0.30–0.45; p < 0.001), from 3.79 to 2.21. Adjusted for baseline severity, no agent differed from haloperidol (olanzapine −0.50, 95% CI −1.04 to 0.05; risperidone −0.23, −0.69 to 0.24). Cumulative incidence of first resolution reached 38.3% (95% CI 27.1–49.4) by day 7 and 46.1% (31.8–59.2) by day 14. Baseline CAM-S was the only variable associated with resolution (hazard ratio 0.49 per point, 0.36–0.67). Physician-documented improvement at discharge (77.9%) far exceeded instrument-based severity control (25.0%).
Conclusions
Prescribing was concentrated on haloperidol while measured severity improved independently of which agent was chosen. The gap between charted improvement and measured outcomes reflects two different constructs, not a treatment effect. These data describe local practice and cannot support causal comparison between agents.
Zitieren
APA
Salazar-Rodríguez, A., Díaz-Bernal, A., Moya-Sánchez, D. N., Ochoa-Madrigal, M. G., Meneses-Luna, O., Espinoza-de-Ávila, E. F., & Cruz-Aviña, F. J. (2026). Antipsychotic Prescribing and Delirium Outcomes at a Mexican Tertiary Referral Center: A Retrospective Cohort. Clinical Pharmacy Connect. https://doi.org/10.69709/cpc.2026.120064
Vancouver
Salazar-Rodríguez A, Díaz-Bernal A, Moya-Sánchez DN, Ochoa-Madrigal MG, Meneses-Luna O, Espinoza-de-Ávila EF, et al. Antipsychotic Prescribing and Delirium Outcomes at a Mexican Tertiary Referral Center: A Retrospective Cohort. Clinical Pharmacy Connect. 2026. doi:10.69709/cpc.2026.120064
BibTeX
@article{SalazarRodrguez2026,
author = {Salazar-Rodríguez, Alejandro and Díaz-Bernal, Alejandro and Moya-Sánchez, Deldhy Nicolás and Ochoa-Madrigal, Marta Georgina and Meneses-Luna, Oscar and Espinoza-de-Ávila, Elia Francisca and Cruz-Aviña, Francisco Javier},
title = {Antipsychotic Prescribing and Delirium Outcomes at a Mexican Tertiary Referral Center: A Retrospective Cohort},
journal = {Clinical Pharmacy Connect},
year = {2026},
doi = {10.69709/cpc.2026.120064}
}
EUVIMED